{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:57:35Z","timestamp":1788886655517,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"crossref","award":["36175"],"award-info":[{"award-number":["36175"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00203-021-02387-3","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T11:03:13Z","timestamp":1621940593000},"page":"3989-3996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessment of the GenoType MTBDRsl VER 2.0 compared to the phenotypic drug susceptibility testing and whole genome sequencing for the rapid detection of resistance to fluoroquinolone and second-line injectable drugs among rifampicin-resistant Mycobacterium tuberculosis isolates"],"prefix":"10.1007","volume":"203","author":[{"given":"Jalil","family":"Kardan-Yamchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirus","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Hamzelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Rahimi Foroushani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Ghodousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Maria","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4825-1170","authenticated-orcid":false,"given":"Mohammad Mehdi","family":"Feizabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"2387_CR1","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1128\/JCM.00051-16","volume":"54","author":"F Brossier","year":"2016","unstructured":"Brossier F, Guindo D, Pham A, Reibel F, Sougakoff W, Veziris N, Aubry A (2016) Performance of the new version (v2. 0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains. J Clin Microbiol 54:1573\u20131580","journal-title":"J Clin Microbiol"},{"key":"2387_CR2","doi-asserted-by":"publisher","first-page":"e0136861","DOI":"10.1371\/journal.pone.0136861","volume":"10","author":"A Catanzaro","year":"2015","unstructured":"Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert M, Georghiou SB, Trollip A, Groessl E, Hillery N (2015) Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis. PLoS ONE 10:e0136861","journal-title":"PLoS ONE"},{"key":"2387_CR3","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1128\/JCM.06664-11","volume":"50","author":"A Engstr\u00f6m","year":"2012","unstructured":"Engstr\u00f6m A, Morcillo N, Imperiale B, Hoffner SE, Jur\u00e9en P (2012) Detection of first-and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J Clin Microbiol 50:2026\u20132033","journal-title":"J Clin Microbiol"},{"key":"2387_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1128\/JCM.01865-16","volume":"55","author":"Y Gardee","year":"2017","unstructured":"Gardee Y, Dreyer A, Koornhof H, Omar S, da Silva P, Bhyat Z, Ismail NA (2017) Evaluation of the GenoType MTBDRsl version 2.0 assay for second-line drug resistance detection of Mycobacterium tuberculosis isolates in South Africa. J Clin Microbiol 55:791\u2013800","journal-title":"J Clin Microbiol"},{"key":"2387_CR5","doi-asserted-by":"publisher","first-page":"e33275","DOI":"10.1371\/journal.pone.0033275","volume":"7","author":"SB Georghiou","year":"2012","unstructured":"Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC (2012) Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS ONE 7:e33275","journal-title":"PLoS ONE"},{"key":"2387_CR6","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1128\/JCM.00039-12","volume":"50","author":"O Ignatyeva","year":"2012","unstructured":"Ignatyeva O, Kontsevaya I, Kovalyov A, Balabanova Y, Nikolayevskyy V, Toit K, Dragan A, Maxim D, Mironova S, Kummik T, Muntean I, Koshkarova E, Drobniewski F (2012) Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multicenter evaluation and feasibility study. J Clin Microbiol 50:1593\u20131597","journal-title":"J Clin Microbiol"},{"key":"2387_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tube.2014.11.003","volume":"95","author":"P Kambli","year":"2015","unstructured":"Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z, Rodwell TC, Catanzaro A, Rodrigues C (2015) Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis 95:137\u2013141","journal-title":"Tuberculosis"},{"key":"2387_CR8","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1128\/JCM.01138-16","volume":"54","author":"K Kaniga","year":"2016","unstructured":"Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A (2016) A multilaboratory, multicountry study to determine MIC quality control ranges for phenotypic drug susceptibility testing of selected first-line antituberculosis drugs, second-line injectables, fluoroquinolones, clofazimine, and linezolid. J Clin Microbiol 54:2963\u20132968","journal-title":"J Clin Microbiol"},{"key":"2387_CR9","doi-asserted-by":"publisher","first-page":"e5895","DOI":"10.7717\/peerj.5895","volume":"6","author":"TA Kohl","year":"2018","unstructured":"Kohl TA, Utpatel C, Schleusener V, de Filippo MR, Beckert P, Cirillo DM, Niemann S (2018) MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates. Peer J 6:e5895","journal-title":"Peer J"},{"key":"2387_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2014.21","volume":"3","author":"J Li","year":"2014","unstructured":"Li J, Gao X, Luo T, Wu J, Sun G, Liu Q, Jiang Y, Zhang Y, Mei J, Gao Q (2014) Association of gyrA\/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerging Microbes Infect 3:1\u20135","journal-title":"Emerging Microbes Infect"},{"key":"2387_CR11","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.4103\/0366-6999.208248","volume":"130","author":"Q Liu","year":"2017","unstructured":"Liu Q, Li G-L, Chen C, Wang J-M, Martinez L, Lu W, Zhu L-M (2017) Diagnostic performance of the GenoType MTBDRplus and MTBDRsl assays to identify tuberculosis drug resistance in Eastern China. Chin Med J 130:1521","journal-title":"Chin Med J"},{"key":"2387_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1128\/AAC.49.2.571-577.2005","volume":"49","author":"CE Maus","year":"2005","unstructured":"Maus CE, Plikaytis BB, Shinnick TM (2005) Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:571\u2013577","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2387_CR13","doi-asserted-by":"publisher","first-page":"1701354","DOI":"10.1183\/13993003.01354-2017","volume":"50","author":"P Miotto","year":"2017","unstructured":"Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, K\u00f6ser CU, Rodwell TC (2017) A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J 50(6):1701354","journal-title":"Eur Respir J."},{"issue":"9","key":"2387_CR14","doi-asserted-by":"publisher","first-page":"e00344","DOI":"10.1128\/AAC.00344-18","volume":"62","author":"PMV Rancoita","year":"2018","unstructured":"Rancoita PMV, Cugnata F, GibertoniCruz AL, Borroni E, Hoosdally SJ, Walker TM, Grazian C, Davies TJ, Peto TEA, Crook DW, Fowler PW, Cirillo DM; CRyPTIC Consortiumfor the CRyPTIC Consortiumfor the CRyPTIC Consortium (2018) Validating a 14-Drug microtiter plate containing bedaquiline and delamanid for large-scale research susceptibility testing of mycobacterium tuberculosis. Antimicrob Agents Chemother 62(9):e00344\u201318","journal-title":"Antimicrob Agents Chemother."},{"key":"2387_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/ers.09.45","volume":"3","author":"E Richter","year":"2009","unstructured":"Richter E, R\u00fcsch-Gerdes S, Hillemann D (2009) Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Respir Med 3:497\u2013510","journal-title":"Expert Rev Respir Med"},{"key":"2387_CR16","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1128\/JCM.01257-15","volume":"53","author":"E Tagliani","year":"2015","unstructured":"Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansj\u00f6 M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A (2015) Diagnostic performance of the new version (v2. 0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol 53:2961\u20132969","journal-title":"J Clin Microbiol"},{"key":"2387_CR17","volume-title":"Anti-Tuberculosis Drug Resistance in the World, Fourth Global Report: The WHO\/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 2002\u20132007","author":"WHO","year":"2008","unstructured":"WHO (2008) Anti-Tuberculosis Drug Resistance in the World, Fourth Global Report: The WHO\/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 2002\u20132007. WHO, Geneva"},{"key":"2387_CR18","volume-title":"WHO Guidelines. 2011. WHO | Guidelines for the programmatic management of drug-resistant tuberculosis","author":"WHO","year":"2011","unstructured":"WHO (2011) WHO Guidelines. 2011. WHO | Guidelines for the programmatic management of drug-resistant tuberculosis. WHO, Geneva"},{"key":"2387_CR19","volume-title":"The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance","author":"WHO","year":"2016","unstructured":"WHO (2016) The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance. WHO, Geneva"},{"key":"2387_CR20","volume-title":"Critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis","author":"WHO","year":"2018","unstructured":"WHO (2018a) Critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. WHO, Geneva"},{"key":"2387_CR21","volume-title":"Global tuberculosis report 2018","author":"WHO","year":"2018","unstructured":"WHO (2018b) Global tuberculosis report 2018. World Health Organization, Geneva (Licence: CC BY-NC-SA 3.0 IGO)"},{"key":"2387_CR22","volume-title":"Treatment guidelines for rifampicin- and multidrug-resistant tuberculosis, 2018 update","author":"WHO","year":"2018","unstructured":"WHO (2018c) Treatment guidelines for rifampicin- and multidrug-resistant tuberculosis, 2018 update. WHO, Geneva"},{"key":"2387_CR23","volume-title":"Global tuberculosis report 2019","author":"WHO","year":"2019","unstructured":"WHO (2019) Global tuberculosis report 2019. World Health Organization, Geneva"},{"key":"2387_CR24","doi-asserted-by":"publisher","first-page":"20004","DOI":"10.1073\/pnas.0907925106","volume":"106","author":"MA Zaunbrecher","year":"2009","unstructured":"Zaunbrecher MA, Sikes RD, Metchock B, Shinnick TM, Posey JE (2009) Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci 106:20004\u201320009","journal-title":"Proc Natl Acad Sci"},{"key":"2387_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.diagmicrobio.2016.06.011","volume":"89","author":"X Zeng","year":"2017","unstructured":"Zeng X, Jing W, Zhang Y, Duan H, Huang H, Chu N (2017) Performance of the MTBDRsl Line probe assay for rapid detection of resistance to second-line anti-tuberculosis drugs and ethambutol in China. Diagn Microbiol Infect Dis 89:112\u2013117","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2387_CR26","first-page":"1320","volume":"13","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Yew W (2009) Mechanisms of drug resistance in Mycobacterium tuberculosis [State of the art series. Drug-resistant tuberculosis. Edited by CY. Chiang. Number 1 in the series]. Int J Tuberc Lung Dis 13:1320\u20131330","journal-title":"Int J Tuberc Lung Dis"},{"key":"2387_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1471-2334-13-240","volume":"13","author":"DV Zimenkov","year":"2013","unstructured":"Zimenkov DV, Antonova OV, Kuz\u2019min AV, Isaeva YD, Krylova LY, Popov SA, Zasedatelev AS, Mikhailovich VM, Gryadunov DA (2013) Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays. BMC Infect Dis 13:240","journal-title":"BMC Infect Dis"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-021-02387-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-021-02387-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-021-02387-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T10:10:06Z","timestamp":1628763006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-021-02387-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2387"],"URL":"https:\/\/doi.org\/10.1007\/s00203-021-02387-3","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}